Ignite Creation Date:
2024-05-06 @ 12:52 AM
Last Modification Date:
2024-10-26 @ 10:55 AM
Study NCT ID:
NCT01674595
Status:
COMPLETED
Last Update Posted:
2013-04-30
First Post:
2012-08-27
Brief Title:
An Open Trial to Assess the Tolerability of AVANZ Olive Immunotherapy
Sponsor:
ALK-Abelló AS
Organization:
ALK-Abelló AS
Study Overview
Official Title:
An Open Trial to Assess the Tolerability of AVANZ Olive Immunotherapy
Status:
COMPLETED
Status Verified Date:
2013-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This trial is an open national multi-centre trial The trial will be initiated after olive pollen season 2012 and subjects will receive treatment for 6 weeks
The aim of study is to assess the tolerability of the up-dosing phase of AVANZ Olive The frequency of patients with adverse reactions will be the primary endpoint
Frequency of patients with systemic reactions according to EAACI classification increase in IgG4 and in IgE and reduction in immediate skin reactivity
The aim of study is to assess the tolerability of the up-dosing phase of AVANZ Olive The frequency of patients with adverse reactions will be the primary endpoint
Frequency of patients with systemic reactions according to EAACI classification increase in IgG4 and in IgE and reduction in immediate skin reactivity
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2011-004852-20 | EUDRACT_NUMBER | None | None |